History & Overview Annual Report President's Pages Center News Community Affairs
Make a Gift Cycle for Survival Fred's Team Rock & Run on the River Yankees Universe Fund Thomas Blake Sr. Memorial Research Fund Donating Blood & Platelets Volunteering Thrift Shop Park Avenue Potluck Cookbook
Press Releases In the News Information for Journalists News@MSKCC
Manhattan New Jersey Long Island Westchester
Working at Memorial Sloan-Kettering Work Sites College Recruitment About Nursing Job Fairs & Career Days Job Search & Apply Online
Making an Appointment

A Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and Stem Cell Transplantation in Patients with B-cell Non-Hodgkin's Lymphoma

[Protocol 06-150]

Full Title :
A NON-MYELOABLATIVE CONDITIONING REGIMEN WITH PERI-TRANSPLANT RITUXIMAB AND THE TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS FROM HLA-COMPATIBLE RELATED OR UNRELATED DONORS IN PATIENTS WITH B CELL LYMPHOID MALIGNANCIES
Purpose :

This study is evaluating a new way of treating patients with cancer of the blood, lymph nodes, and/or bone marrow that is unlikely to be cured by chemotherapy and or radiation alone. Doctors think the best way to treat these patients is with a transplant of blood-forming stem cells from a compatible healthy donor, following a conditioning regimen with low doses of chemotherapy and radiation.

A conditioning regimen is a combination of drugs and radiation therapy that are given right before the transplant. The conditioning regimen being assessed in this study includes low doses of chemotherapy, low-dose radiation therapy, and rituximab (a drug approved for treating non-Hodgkin's lymphoma).

Recent studies have shown that regimens that use lower doses of chemotherapy and radiation can be used to prepare a patient for a transplant of blood-forming cells, and that the immune cells (T cells) in a transplant from a normal donor can destroy lymphoma cells anywhere in the body (the "graft-versus-lymphoma" effect).

Eligibility :

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have non-Hodgkin's lymphoma that has relapsed, or is aggressive and at high risk for relapse. Patients' tumors must contain the CD20 antigen (which is necessary for rituximab to work).
  • Patients may not have had a prior stem cell transplant from a donor.
  • Patients must have an HLA-matched donor.
  • Patients must be age 18-70.

For more information and to see if you are eligible for this study, please contact Dr. Hugo Castro-Malaspina at 212-639-8197.

Back to All Clinical Trials
Bookmark and SharePrintEmail This Page